Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Apollomics, Inc. before investing.

In this article, we go over a few key elements for understanding Apollomics, Inc.’s stock price such as:

• Apollomics, Inc.’s current stock price and volume
• Why Apollomics, Inc.’s stock price changed recently
• Upgrades and downgrades for APLM from analysts
• APLM’s stock price momentum as measured by its relative strength

About Apollomics, Inc. (APLM)

Before we jump into Apollomics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.

Want to learn more about Apollomics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Apollomics, Inc..

Apollomics, Inc.’s Stock Price as of Market Close

As of August 20, 2026, 3:31 PM, CST, Apollomics, Inc.’s stock price was $23.570.

Apollomics, Inc. is down 0.08% from its previous closing price of $23.590.

During the last market session, Apollomics, Inc.’s stock traded between $22.790 and $24.430. Currently, there are approximately 1.79 million shares outstanding for Apollomics, Inc..

Apollomics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Apollomics, Inc. Stock Price History

Apollomics, Inc.’s (APLM) price is currently up 36.68% so far this month.

During the month of August, Apollomics, Inc.’s stock price has reached a high of $27.160 and a low of $0.000.

Over the last year, Apollomics, Inc. has hit prices as high as $42.120 and as low as $3.659. Year to date, Apollomics, Inc.’s stock is up 26.08%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Apollomics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 19, 2026, there were analysts who downgraded Apollomics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Apollomics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Apollomics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Apollomics, Inc. (APLM) by visiting AAII Stock Evaluator.

Relative Price Strength of Apollomics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 19, 2026, Apollomics, Inc. has a weighted four-quarter relative price strength of 47.73%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Apollomics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Apollomics, Inc. Stock Price: Bottom Line

As of August 20, 2026, Apollomics, Inc.’s stock price is $23.570, which is down 0.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Apollomics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.